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OBJECTIVES We sought to investigate the relationship among C-reactive protein (hs-CRP), clinical
characteristics, exercise stress test responses, and ST-segment changes during daily life in
patients with typical chest pain and normal coronary angiograms (CPNCA).
BACKGROUND Patients with CPNCA have coronary microvascular endothelial dysfunction and myocardial
ischemia. Elevated hs-CRP levels have been related to atherogenesis and endothelial
dysfunction. The relationship between hs-CRP and disease activity has not been previously
investigated in CPNCA patients.
METHODS We studied 137 consecutive CPNCA patients (mean age, 57  9; 33 men). All completed
standardized angina questionnaires, underwent exercise stress testing, 24-h ambulatory
electrocardiogram (ECG) monitoring (Holter), and hs-CRP measurements at study entry.
RESULTS C-reactive protein levels (mg/l) were higher in patients with frequent (2.9  3.3) and
prolonged (3.9  4.1) chest pain episodes, and in those with ST-segment depression on
exercise testing (2.6  2.8) and Holter monitoring (3.4  3.1) compared with patients with
occasional (1.3  1.2; p  0.002) or shorter chest pain (1.5  1.3; p  0.001) episodes,
negative exercise stress testing (1.1  1.1; p  0.001), and no ST-segment shifts on
Holter monitoring (0.9  0.7; p  0.001). Moreover, we found a correlation between
hs-CRP concentration and number of ischemic episodes during Holter monitoring (r 
0.65; p  0.001) and with the magnitude of ST-segment depression on exercise testing
(r  0.43; p  0.001). The hs-CRP was the only independent variable (multivariate
logistic regression) capable of predicting positive findings on Holter monitoring (odds
ratio [OR], 3.8; confidence interval [CI], 2.3 to 6.2) and exercise testing (OR, 1.7; CI,
1.2 to 2.2).
CONCLUSIONS The hs-CRP correlates with symptoms and ECG markers of myocardial ischemia in
CPNCA patients. Whether hs-CRP is related to the pathogenesis of angina in these patients
deserves further investigation. (J Am Coll Cardiol 2003;41:1468–74) © 2003 by the
American College of Cardiology Foundation
Chest pain suggestive of myocardial ischemia in patients
with normal coronary angiograms (CPNCA) is often non-
cardiac in origin. However, a proportion of these patients
who have typical exertional chest pain and a positive exercise
stress test response (syndrome X) (1) have transient myo-
cardial perfusion abnormalities (2) and metabolic evidence
of myocardial ischemia (3) in response to appropriate
stimuli.
Coronary microcirculation abnormalities have been
shown to play a pathogenic role in cardiac syndrome X.
Endothelial cell activation (4,5) and coronary endothelial
dysfunction (6,7) have been reported in patients with
syndrome X. These may be associated with an increased
release of constricting factors and the production of proin-
flammatory cytokines, cell adhesion molecules, and growth
factors, which, in turn, can induce inflammatory and pro-
liferative changes in the vessel wall and cause microvascular
dysfunction (8). Recently, we reported higher intercellular
cell adhesion molecule-1 (ICAM-1) and vascular cell adhe-
sion molecule-1 (VCAM-1) levels in patients with cardiac
syndrome X, compared with healthy individuals (9). Cox et
al. (10) reported a relationship between coronary vasomotor
abnormalities during rapid atrial pacing and endothelin-1
(ET-1) concentrations in CPNCA patients. Thus, in-
creased ET-1 levels may be associated with coronary mi-
crovascular endothelial dysfunction and contribute to re-
duced vasodilatory reserve in patients with CPNCA.
C-reactive protein (CRP), a marker of systemic inflam-
mation, has been shown to be elevated in patients with
angina and to correlate with impaired systemic endothelial
vascular reactivity (11). It has been also suggested that CRP
contributes to the development of endothelial dysfunction
and atherogenesis (12).
We sought to investigate whether CRP levels correlate
with markers of disease activity, such as chest pain occur-
rence and duration, ST-segment shifts on Holter monitor-
ing during daily life, and a positive response to exercise
stress testing in patients with CPNCA.
From the Coronary Artery Disease Research Unit, Department of Cardiological
Sciences, St. George’s Hospital Medical School, London, United Kingdom. Dr.
Cosı´n-Sales is the recipient of a research scholarship from the Spanish Society of
Cardiology.
Manuscript received September 11, 2002; revised manuscript received November
12, 2002, accepted December 12, 2002.
Journal of the American College of Cardiology Vol. 41, No. 9, 2003
© 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00
Published by Elsevier Inc. doi:10.1016/S0735-1097(03)00243-2
METHODS
Patients. We studied 164 consecutive patients who were
referred to our CPNCA clinic from September 1996 to
February 2002. All had typical anginal chest pain on effort
and/or at rest, and completely normal coronary angiograms.
As part of their clinical characterization, all patients under-
went clinical and risk factor assessment, baseline 12-lead
electrocardiogram (ECG), M-mode and two-dimensional
echocardiography, and provocative testing for coronary
artery spasm with hyperventilation or ergonovine.
Ten patients with left bundle branch block on the
baseline ECG, two with dilated cardiomyopathy, six with
coronary artery spasm, five with systemic inflammatory
conditions, and one with prostatitis were excluded. In
addition, three patients who returned an incomplete angina
questionnaire were also excluded from study.
We, thus, enrolled 137 patients (mean age, 57  9 years;
33 men), all of whom completed a standardized angina and
cardiovascular risk factor questionnaire and also underwent
exercise treadmill stress testing and 24-h continuous ECG
Holter monitoring. Venous blood samples were taken at
study entry and kept frozen at 80°C for measurement of
serum high-sensitivity C-reactive protein (hs-CRP) con-
centration at a later time.
The study protocol was approved by the local research
ethics committee, and all subjects signed informed written
consent before study entry.
Angina and cardiovascular risk factor questionnaires.
Temporal onset of pain, number of anginal episodes per
week, average duration of episodes, triggers of chest pain,
association of chest pain with exertion, presence of chest
pain at rest, and classical risk factors such hyperlipidemia,
diabetes mellitus, hypertension, and current or past smoking
were investigated.
Chest pain weekly occurrence was subsequently grouped
in three categories: 2, 2 to 4, and 5 episodes per week.
Average duration of individual anginal episodes was also
grouped in three categories: 5, 5 to 20, and20 min. The
circumstance of occurrence of angina was also noted, that is,
exertional chest pain, pain at rest, and their combination.
24-h continuous ambulatory ECG monitoring. Three-
channel 24-h Holter monitors with amplitude-modulated
recording (Marquette 8500, Marquette Electronics Inc.,
Milwaukee, Wisconsin) were used to record ST-segment
changes during patients routine daily activities; ST-segment
analyses (Marquette 8000 laser Holter, version 5) were
performed after each recording was completely edited and
artifacts removed. Ischemic episodes were defined as hori-
zontal or downsloping ST-segment depression 1.0 mm
(0.1 mV) measured at 0.08 s after the J-point and persisting
for 1 min. Holter recordings were analyzed independently
by two investigators who were blind to the patients’ clinical
data.
Treadmill exercise stress testing. All treadmill exercise
tests were carried out in the morning between 9:00 AM and
10:30 AM after patients discontinued cardiac medications for
at least 48 h. The Bruce protocol was used in all patients
(CASE Marquette 12, Marquette Electronics, Milwaukee,
Wisconsin). Three ECG leads (V2 to V5 and aVF) were
continuously monitored during the test. A standard 12-lead
ECG was printed and blood pressure measured (cuff sphyg-
momanometer) at baseline, at the end of each stage, at peak
exercise, as well as at the onset of chest pain and/or
significant ST-segment depression. Time to 1-mm ST-
segment depression and total exercise time were recorded.
Patients’ recovery was continuously monitored until the
return of ST-segment to baseline levels, or for up to 6 min
when tests were negative.
The exercise test was terminated when one or more of the
following end points were reached: physical exhaustion,
progressive severe angina, ST-segment depression 3 mm,
dyspnea, and severe arrhythmias.
A test was considered “positive” when 1 mm ST-
segment (horizontal or downsloping) at 0.08 s from the
J-point was observed in two contiguous leads. In patients
with positive test results, duration of exercise, heart rate-
blood pressure product at 1 mm ST-segment depression and
at peak exercise, and total ST-segment depression (mm)
were measured. In patients with negative tests results,
duration of exercise and rate pressure product were mea-
sured at peak exercise.
CRP assessment. Fasting blood samples were collected in
tubes containing citrate, and were drawn and centrifuged
immediately. Serum was then aliquoted and stored at
80°C until analysis. No specimen inadvertently thawed
during storage. C-reactive protein measurements were per-
formed on the COBAS Integra (Roche Diagnosis Limited,
East Sussex, United Kingdom) using the CRP-latex assay in
both the high-sensitivity application (analytical range, 0.2 to
12 mg/l) and the normal application (analytical range, 2 to
160 mg/l). Analytical precision of the hs-CRP–latex assay
was 7.6% at a level of 1.02 mg/l, 3.3% at 1.79 mg/l, and
1.3% at a level of 4.36 mg/l. Samples outside the analytical
range of the hs-CRP–latex assay were analyzed by the
CRP-latex assay in the normal application. The analytical
precision of the normal CRP-latex assay was 2.4% at a level
of 29.5 mg/l and 1.3% at a level of 113 mg/l.
Statistical analysis. Baseline demographic and biochemis-
try analytical information is presented as mean  SD for
continuous variables and as absolute number (percentage)
Abbreviations and Acronyms
CI  confidence interval
CPNCA  chest pain and normal coronary arteriogram
CRP  C-reactive protein
ECG  electrocardiogram
ET-1  endothelin-1
hs-CRP  high-sensitivity C-reactive protein
ICAM-1  intercellular cell adhesion molecule-1
OR  odds ratio
VCAM-1  vascular cell adhesion molecule-1
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for categorical variables. Comparison of hs-CRP levels
among patients with different chest pain duration, different
number of weekly episodes, and different circumstances of
occurrence of angina was carried out with one-way analysis
of variance. When this analysis showed statistical signifi-
cance, post-hoc Bonferroni test was applied to assess indi-
vidual differences. To evaluate whether cardiovascular risk
factors would alter these results, univariate analysis of
variance was carried out. Comparison of hs-CRP levels
among patients with positive or negative exercise stress test
or Holter monitoring was carried out using the Student t
test. To assess the relationship of the results of exercise
stress testing and 24-h ECG monitoring with the severity of
anginal symptoms, the chi-square test was applied. The
Spearman rank correlation test was used to assess the
relation between hs-CRP concentration and ST-segment
depression in the 24-h Holter, the maximal ST-segment
depression and the heart rate-blood pressure product at
1-mm ST-segment depression in the exercise stress test.
Logistic regression analysis was carried out to assess inde-
pendent predictors for positive (1 mm ST-segment de-
pression) or negative (1 mm ST-segment depression)
exercise stress test and Holter results.
Traditional risk factors used in the multivariable analyses
included smoking history, diabetes, diagnosis of hyperten-
sion, and cholesterol levels. Statistical analysis was per-
formed using SPSS for Windows (version 10.0, SPSS Inc.,
Chicago, Illinois). All p values are two-tailed, and confi-
dence intervals (CI) have been calculated at the 95% level.
RESULTS
Baseline demographic characteristics, classical risk factors,
and medical treatment at study entry are shown in Table 1.
The characteristics of chest pain in all 137 patients are
presented in Table 2. Episodes of chest pain were often
prolonged (72% of patients had chest pain episodes 5
min). All patients had exertional chest pain, but 53% of
them also had chest pain at rest. Rest chest pain was the
predominant symptom in only 10% of patients. Regarding
weekly occurrence of chest pain, 39% of patients had 5
chest pain episodes per week.
Exercise stress test responses were positive in 86 (63%)
patients, and 61 (45%) patients had at least one transient
ischemic episode on ECG Holter monitoring. Three re-
cordings (2%) were excluded from analyses due to technical
problems. The average number of ST-segment depressions
per patient was 2.1  1.4 (range, 1 to 8).
We did not find a relationship between exercise stress test
or 24-h ECG Holter monitoring results and the number of
chest pain episodes per week or the duration of chest pain
episodes (Table 3).
Clinical characteristics and hs-CRP levels. Baseline hs-
CRP levels in the whole patient population ranged from 0.1
to 17.2 mg/l (mean 2.0  2.5 mg/l).
Patients with prolonged angina episodes (20 min) had
significantly higher hs-CRP levels (3.9  4.1 mg/l) than
patients with moderate (5 to 20 min) duration of pain (1.5
 1.4 mg/l; p  0.001) and those with short-lasting (5
min) episodes (1.5  1.3 mg/l; p  0.001). Similarly,
patients with a greater number of chest pain episodes (5
per week) had significantly higher levels of hs-CRP (2.9 
3.3 mg/l) than patients with two to four episodes (1.6 1.7
mg/l; p  0.015) and those with 2 episodes of chest pain
(1.3  1.2 mg/l; p  0.004), as shown in Figure 1. These
significant differences were maintained after adjustment for
traditional risk factors; hs-CRP concentration was nonsig-
nificantly (p  0.6) higher in patients with both exertional
and rest pain (2.2  2.5 mg/l) compared with patients with
exertional chest pain only (1.8  2.5 mg/l) or those with
predominantly rest chest pain (1.7  1.7 mg/l).
Exercise stress testing, 24-h ECG Holter data, and
hs-CRP levels. In patients with a positive exercise stress
test, hs-CRP level was significantly higher (2.6  2.8 mg/l)
than in patients with a negative exercise stress test result (1.1
 1.1 mg/l; p  0.001). Similarly, patients with ischemic
Table 1. Baseline and Clinical Characteristics of 137 CPNCA
Patients Included in the Study
Patients (n) 137
Age, yrs 57.2  8.8
Women, n (%) 104 (75.9)
Smoking status, n (%)
Current smokers 17 (12.4)
Never smoked 75 (54.8)
Former smokers 45 (32.8)
Risk factors, n (%)
Hypertension 70 (51.1)





Ca-channel antagonists 87 (63.5)
Lipid-lowering agents 34 (24.8)
Aspirin 71 (51.8)
ACE-inhibitors 21 (15.3)
Values are mean  SD except where otherwise indicated.
ACE  angiotensin-converting enzyme; CPNCA  chest pain and normal
coronary arteriogram.







5 min 39 (28%)
5–20 min 67 (49%)
20 min 31 (23%)
Chest pain relation
Only exertional 51 (37%)
Mainly rest 14 (10%)





CPNCA  chest pain and normal coronary arteriogram.
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episodes during 24-h Holter monitoring had higher hs-
CRP levels (3.4  3.1 mg/l) compared with patients
without ST-segment shifts (0.9  0.7 mg/l; p  0.001).
These differences remained significant after adjustment for
traditional risk factors.
The number of ischemic episodes during the 24-h ECG
Holter monitoring was significantly correlated with hs-CRP
concentration (Spearman r  0.65; p  0.001). When
analysis was limited to the 86 patients with a positive
exercise stress test result, both ST-segment depression at
peak exercise and rate pressure product at 1-mm ST-
segment depression correlated significantly with hs-CRP
levels (Spearman r  0.43; p  0.001 and Spearman r 
0.42; p  0.001, respectively) (Fig. 2).
Binary logistic regression showed that hs-CRP was the
only variable able to predict exercise stress test results (odds
ratio [OR], 1.7; 95% CI, 1.2 to 2.2) and the presence of
ST-segment depression episodes during 24-h ECG Holter
monitoring (OR, 3.8; 95% CI, 2.3 to 6.2).
DISCUSSION
The present study showed, for the first time, that CRP
levels are higher in CPNCA patients who have increased
clinical activity, that is, more frequent and prolonged chest
pain episodes, positive exercise stress test responses, and
ischemic episodes during 24-h Holter recordings, compared
with those with a reduced number and a shorter duration of
chest pain episodes, negative exercise test responses, and
absence of ST-segment changes on Holter monitoring.
Findings in this study confirm and expand recent prelimi-
nary observations (13) that syndrome X patients have higher
baseline CRP levels than healthy subjects. In the present
study, CRP serum concentration was the only independent
variable able to predict both a positive result of exercise
ECG stress testing and the presence of ST-segment shifts
on Holter monitoring. Of importance, syndrome X patients
with lower ischemic thresholds, as assessed by heart rate-
blood pressure product levels at 1-mm ST-segment depres-
sion on exercise and those with a larger number of episodes
of ST-segment depression on Holter monitoring, had
significantly higher CRP levels compared with patients with
higher ischemic thresholds.
C-reactive protein is a sensitive, albeit nonspecific,
marker of inflammation that increases in response to acute
injury, infection, and other inflammatory stimuli. It may be,
therefore, speculated that CRP levels in our study were
elevated merely due to the presence of chest pain. However,
this is unlikely to be the case, as CRP levels were increased
in patients with ST-segment changes and positive exercise
ECG responses irrespective of the presence or absence of
chest pain. Moreover, chest pain duration or severity did not
correlate significantly with ECG changes in our patients,
further suggesting high hs-CRP levels were not simply a
nonspecific response to pain. The observed relationship
between ECG ischemic changes and hs-CRP levels in this
study together with findings in large epidemiological trials
that high CRP levels were a risk factor for cardiovascular
events in both apparently healthy individuals (14) and
angina patients (15,16) suggests that inflammation may
have a pathogenic role in cardiac syndrome X.
C-reactive protein plasma levels have been shown to
correlate with endothelial dysfunction (11,12,17), and in-
creased levels of ET-1 and other markers of endothelial
activation (4,5) and dysfunction (18–20) have been previ-
ously reported in these patients.
CRP, endothelial dysfunction, and myocardial ischemia
in syndrome X. Yudkin et al. (17) showed in a cross-
sectional study of healthy subjects that CRP concentrations
were related to biochemical markers of endothelial dysfunc-
tion. Fichtlscherer et al. (11) reported that elevated CRP
levels in patients with coronary artery disease were associ-
ated with a profound impairment of systemic endothelial
vascular reactivity. More importantly, they also reported
that normalization of CRP levels over time was associated
with a significant improvement of endothelium-dependent
flow responses. Further data endorsing a role of CRP in
endothelial dysfunction were gathered by Pasceri et al. (12),
who reported that CRP induced the expression of ICAM-1
and VCAM-1 in both umbilical vein and coronary artery
endothelial cells. These findings suggest that CRP was not
Table 3. Relationship Between Exercise Stress Testing Responses, Holter Monitoring Results,
and Severity of Anginal Symptoms
Exercise Stress Test Result
p Value
24-h Holter Result
p ValueNegative Positive Negative Positive
Chest pain duration
5 min 11 (8%) 28 (20%) 0.3 22 (16%) 16 (12%) 0.2
5–20 min 29 (21%) 38 (28%) 39 (29%) 27 (20%)
20 min 11 (8%) 20 (15%) 12 (9%) 18 (14%)
Number of chest pain
episodes per week
2 18 (13%) 22 (16%) 0.4 25 (19%) 13 (9%) 0.2
2–4 16 (12%) 28 (21%) 23 (17%) 20 (15%)
5 17 (12%) 36 (26%) 25 (19%) 28 (21%)
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merely an inflammatory marker but also a potential cause of
impaired endothelial function.
We have previously shown that plasma ET-1, a powerful
microvascular vasoconstrictor agent, is raised in patients
with syndrome X and that “high” plasma ET-1 levels were
associated with an earlier onset of chest pain during exercise
(4) and with a reduced coronary flow response during rapid
atrial pacing (10). Recently, Desideri et al. (5) found that
syndrome X patients had an increased responsiveness of
ET-1 to glucose loading, suggesting that these patients were
more susceptible to releasing ET under stressful circum-
stances.
The mechanisms responsible for myocardial ischemia in
patients with CPNCA remain poorly understood, but
increased vasoconstrictor and abnormal vasodilator re-
sponses, due to endothelial dysfunction, have been sug-
gested as possible candidates (6,7). Reversible myocardial
perfusion defects in areas supplied by arteries showing
endothelial dysfunction, the production of transmyocardial
lactate (21), lipid hydroperoxides and conjugated dienes
(22) during atrial pacing, and a decrease of pH and oxygen
saturation (23) in the coronary sinus of patients with
syndrome X undergoing atrial pacing, indicate that myocar-
dial ischemia may indeed be responsible for chest pain and
ECG changes in these patients. More recently, using
cardiac magnetic resonance, Buchthal et al. (3) and Panting
et al. (2) have objectively shown the presence of myocardial
ischemia in syndrome X patients.
Figure 1. Error bars graph showing high-sensitivity C-reactive protein (hs-CRP) concentrations (mean  2 SE) compared with number of chest pain
episodes per week (A) and duration of chest pain episodes (B).
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Previous studies from our group showed the occurrence
of increased ICAM-1 and VCAM-1 levels in syndrome X
patients that were comparable to elevations in coronary
artery disease patients and significantly larger than levels
found in healthy individuals (9). Taken together, these
findings and the results of the present study suggest that
inflammatory mechanisms may be responsible, at least in
part, for endothelial dysfunction and increased disease
activity in patients with cardiac syndrome X.
Conclusions. High-sensitivity C-reactive protein corre-
lates with symptoms and ECG markers of myocardial
ischemia in CPNCA patients. Whether hs-CRP is related
to the pathogenesis of angina in these patients deserves
further investigation.
Figure 2. Spearman correlations among high-sensitivity C-reactive protein (hs-CRP) concentrations, number of episodes of ST-segment depression during
24-h electrocardiogram Holter monitoring (A), ST-segment depression during exercise stress testing (B), and rate-pressure product (RPP) at 1-mm
ST-segment depression during exercise stress testing (C).
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